{"title":"tenecteplase治疗急性中风的前景:可以批准还是无法批准?","authors":"Kori S Zachrison, Lee H Schwamm","doi":"10.1016/j.medj.2022.09.005","DOIUrl":null,"url":null,"abstract":"<p><p>Reperfusion is critical for improving outcomes of patients experiencing ischemic stroke. Increasing evidence supports tenecteplase as an alternative to alteplase, with many potential benefits. This article discusses the current state of the evidence for intravenous reperfusion and considers strategies for improving access, including possible modifications to efficacy-related regulatory updates.</p>","PeriodicalId":272244,"journal":{"name":"Med (New York, N.y.)","volume":" ","pages":"651-655"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The promise of tenecteplase in acute stroke: Within reach or beyond approval?\",\"authors\":\"Kori S Zachrison, Lee H Schwamm\",\"doi\":\"10.1016/j.medj.2022.09.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Reperfusion is critical for improving outcomes of patients experiencing ischemic stroke. Increasing evidence supports tenecteplase as an alternative to alteplase, with many potential benefits. This article discusses the current state of the evidence for intravenous reperfusion and considers strategies for improving access, including possible modifications to efficacy-related regulatory updates.</p>\",\"PeriodicalId\":272244,\"journal\":{\"name\":\"Med (New York, N.y.)\",\"volume\":\" \",\"pages\":\"651-655\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Med (New York, N.y.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.medj.2022.09.005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/10/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Med (New York, N.y.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.medj.2022.09.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
The promise of tenecteplase in acute stroke: Within reach or beyond approval?
Reperfusion is critical for improving outcomes of patients experiencing ischemic stroke. Increasing evidence supports tenecteplase as an alternative to alteplase, with many potential benefits. This article discusses the current state of the evidence for intravenous reperfusion and considers strategies for improving access, including possible modifications to efficacy-related regulatory updates.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
